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Introduction
Esophageal cancer is the sixth most common cause of cancer-related death worldwide (1) . Esophageal squamous cell carcinoma (ESCC), one of the major histopathological subtypes of esophageal cancer, is the fourth most prevalent malignancy in China (2, 3) . Most ESCC patients are diagnosed with advanced diseases that responds poorly to chemotherapy. Concurrent chemo/radiotherapy is currently the standard of care in the nonsurgical management of advanced esophageal cancer (4) . Cisplatin (cis-diaminedichloroplatinum (II)) combined with 5-fluorouracil (5-FU) is a classical regimen that is used to treat ESCC clinically. The anticancer effects of cisplatin are mediated via apoptosis induced by DNA adducts, which activate several proapoptotic signal transduction pathways (5).
Apoptosis is essential for normal development and plays an important role in the responsiveness to chemotherapy and radiotherapy. Apoptosis is triggered by two major intracellular signaling cascades the intrinsic pathway (mitochondrial pathway) and the extrinsic pathway (death receptor pathway) (6) . Both apoptotic pathways result in caspase activation and cleavage of specific cellular substrates, eventually leading to cell death. Apoptosis is tightly controlled by complex regulatory networks, and de-regulation of apoptosis contributes to pathological disorders such as cancer and therapeutic resistance to tumors (7) .
The intrinsic apoptotic pathway is mediated by mitochondria and activated in response to intracellular stresses including oncogene activation and DNA damage.
During the intrinsic apoptotic process, several apoptogenic proteins are released from within the intermembrane space of the mitochondria; Smac is released from mitochondria in response to anticancer drug stimuli and promotes apoptosis by antagonizing inhibitor of apoptosis proteins (IAPs) (8) (9) (10) (11) . Recent work suggests that Smac-mediated apoptosis is important for the apoptotic responses induced by several anticancer agents, including certain chemopreventive agents (10) (11) (12) (13) (14) .
Accumulating evidence shows that Smac is a possible target for anticancer therapy.
The combination of Smac activation with classical anticancer drugs seems to be a rational therapeutic approach (15, 16) . Overexpression of Smac and chemically synthesized Smac mimetics can enhance apoptosis induced by chemotherapy and radiotherapy in several types of tumor cells (12, 13, (17) (18) (19) (20) (21) . Smac expression has been detected in a variety of normal and tumor tissues, but the expression varies among different tumor types (22) (23) (24) (25) (26) . However, little is known about the expression and role of Smac in esophageal cancer. We hypothesized that Smac expression is altered in ESCC and differential Smac expression contributes to differential chemotherapy response. To better understand the role of Smac in the chemotherapy of esophageal cancer, we assessed Smac expression with tissue microarrays (TMAs) of ESCC with immunohistochemical staining. We also investigated the molecular mechanisms by which Smac mediates cisplatin-induced apoptosis in esophageal cancer cells.
Research. Health Organization (WHO) criteria. The diagnostic examinations consisted of esophagography, computed tomography, chest x-ray, abdominal ultrasonography and bone scan when necessary to detect recurrence or metastasis. All patient clinical parameters were summarized in supplementary Table 1 and Table 2 .
Immunohistochemical staining. For IHC staining, the TMAs were incubated with an antibody against Smac or control IgG (1 ȝg/ml). After washing with PBS, TMAs were incubated with a biotin-labeled secondary antibody. Signals were visualized using an ultrasensitive streptavidin-peroxidase system (Maxim Biotech, Fuzhou, China). The intensity of Smac staining and the percentage of Smac-positive cells were scored as described (27) . The results were scored independently by two pathologists based on the intensity of Smac staining and the extent of Smac expression. Intensity of Smac staining was scored as 0 (negative), 1 (weak), or 2 (strong). The extent of expression was scored based on the percentage of positive cells: 0 (negative), 1 (1%-25%), 2 (26%-50%), 3 (51%-75%), and 4 (76%-100%). The overall score of each case was a sum of the intensity of staining and extent of expression scores. Overall scores that are equal or higher than 4 were defined as positive staining, while those below 4 as negative staining. Table 3 .
To investigate whether Smac expression correlated with the chemotherapeutic response, we analyzed 31 ESCC cases who had undergone cisplatin-based chemotherapy ( Figure 1 and Table 1 ). Smac expression was significantly associated with the chemotherapeutic response. Positive Smac staining was significantly more intense (P = 0.019) in the CR/PR groups compared to the SD/PD groups (Table 1) .
However, the presence of Smac in these ESCC tissues did not obviously correlate with other clinical and pathologic characteristics, including the patients' age, gender, and tumor histopathological features (Table 1) . 
Smac deficiency leads to cisplatin resistance in vivo.
To determine whether Smac deficiency causes cisplatin resistance in vivo, an equal Figure 4C ); in contrast, the size of the parental EC0156 tumors was significantly decreased (P = 0.001; Figure 4C ). Thus, Smac deficiency can cause cisplatin resistance in vivo.
Smac mimetics restore cisplatin-induced apoptosis in Smac-KD cells.
Smac binds to IAPs through its N-terminal four residues (AVPI) to relieve the inhibition of caspase-9 and caspase-3 (31, 32). Smac mimetics can induce degradation of cellular IAP1 and sensitize cancer cells to apoptosis induced by anticancer agents (33) (34) (35) . Therefore, we explored whether Smac mimetics could restore cisplatin-induced apoptosis in Smac-KD cells by analyzing LBW242, a Smac mimetic of AVPI (12, 19) . LBW242 greatly sensitized Smac-KD cells to cisplatin-induced apoptosis, but had a smaller effect on the parental EC0156 cells ( Figure 5A, B) , as confirmed by annexin V/PI staining ( Figure 5C ). LBW242 also enhanced caspase-9 activation and cytochrome c release in response to cisplatin treatment ( Figure 5D ). 
Discussion
Approximately half of patients diagnosed with esophageal cancer present with overt metastatic disease, and advanced metastatic disease is treated with chemotherapy. ESCC patients often receive combination chemotherapy involving conventional chemotherapeutics such as cisplatin, 5-FU, etoposide, and paclitaxel (4).
Despite the use of the cisplatin/5-FU combination, there is no convincing evidence for significant improvement in the overall survival rate. Previous studies showed an association between Smac expression and tumor progression, poor prognosis, and altered responses to diverse stimuli in many human cancers (25, (36) (37) (38) (39) (40) . However, the role of Smac in ESCC remains unclear. Thus, we studied Smac in ESCC patients, including those who had undergone chemotherapy. We observed Smac was frequently down-regulated in ESCC, with only 36.8% (25/68) of ESCC tissues expressing Smac, compared to 64.7% (44/68) of matched adjacent normal tissues. Thus, Smac downregulation may contribute to esophageal carcinogenesis. Reduced Smac expression has also been described in other types of cancer (11, 38, (40) (41) (42) .
Importantly, our data revealed a significant association between Smac expression and chemotherapeutic response among the 31 ESCC patients who had undergone chemotherapy. Smac staining was observed more frequently in the CR+PR group than (50) . Apoptosis induced by multiple apoptotic stimuli is in Smac-deficient mice, suggesting a redundant role for Smac and compensation for the absence of Smac function by other molecules during apoptosis (51) . Therefore, the requirement for Smac in apoptosis appears to be dependent on specific stimuli and cell types.
The mitochondrial apoptotic pathway is generally thought to involve translocation of cytochrome c from mitochondria into cytosol, which results in activation of caspase 9 and caspase 3. However, cytochrome c-independent activation of caspases has also been described. For example, Greil and his colleagues have shown that activation of caspase 9 by resveratrol does not require cytochrome c release (52).
Hishita and his colleagues reported that caspase 3 could be activated by lysosomal 
22 enzymes in cytochrome c-independent apoptosis induced by etoposide in P39 cells (53) . It has been shown that procaspase-9 is a substrate of caspase 12, and that ER stress induced a specific cascade response involving caspases 12, 9, and 3 in a cytochrome c-independent manner (54). In our study, we could not detect cytochrome c release in EC0156 cells treated with cisplatin for 12 h, despite the clear effects of cisplatin on the mitochondrial membrane potential and caspase activation. This observation may be explained by cytochrome c-independent early activation of caspase 9 or caspase 3 in EC0156 cells treated with cisplatin for 12 h. At a later time point (24 h), the release of cytochrome c may enhance the activation of caspase 9 and caspase 3, and further amplify apoptotic signals.
Structural and biochemical studies have shown that the proapoptotic function of
Smac is mediated through its N-terminal AVPI motif, which binds to one or more IAP repeat domain in IAPs and antagonizes IAP-mediated inhibition of caspase activation (18, 19) . Smac overexpression and agents that mimic the AVPI motif can sensitize cancer cells to several chemotherapeutic agents (55) (56) (57) (58) (59) . We found that LBW242, a 7-mer small-molecule Smac mimetic (19) Values are expressed as n (%). Statistically significant at P 0.05. a OR = odds ratio; CI = confidence interval; CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease.
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